HTD.MU - CORCEPT THERAPEUTICS INC.
| Previous Close | 12.00 |
| Open | 12.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 12.00 - 12.00 |
| 52 Week Range | 8.75 - 15.60 |
| Volume | 100 |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
Hedge Funds Are Buying Corcept Therapeutics Incorporated (CORT)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- Insider Monkey
Did Hedge Funds Drop The Ball On Corcept Therapeutics Incorporated (CORT) ?
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
Motley FoolCorcept Therapeutics Incorporated (CORT) Q2 Earnings Call Transcript
CORT earnings call for the period ending June 30, 2019.
- Motley Fool
Corcept Therapeutics Incorporated (CORT) Q1 2019 Earnings Call Transcript
CORT earnings call for the period ending March 31, 2019.
- Associated Press
Corcept: 1Q Earnings Snapshot
The Menlo Park, California-based company said it had net income of 15 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The drug developer posted revenue of $64.8 million ...
- Motley Fool
Here's Why Corcept Therapeutics Shares Rose 11.5% in February
The stock ricocheted around, but ultimately posted a monthly gain.
GuruFocus.comShort Squeeze on Corcept Therapeutics
Corcept Therapeutics Inc. (CORT) is one of them. Warning! GuruFocus has detected 3 Warning Signs with CORT. With Corcept set to earn upwards of $1 per share in 2019, it is probably fairly valued at its current cap.
Motley FoolCorcept Therapeutics Incorporated (CORT) Q4 2018 Earnings Conference Call Transcript
CORT earnings call for the period ending December 31, 2018.
- Motley Fool
Here's Why Corcept Therapeutics Fell as Much as 13.7% Today
The company announced preliminary full-year 2018 results that fell below Wall Street's expectations.
- Motley Fool
Here's Why Corcept Therapeutics Stock Fell as Much as 18.5% Today
An investigative report is shining light on some very serious questions about the company. Shareholders absolutely must read it.
